Glycemic Variability and Diabetes Complications: Does It Matter? Simply Put, There Are Better Glycemic Markers!
暂无分享,去创建一个
[1] L. Kessler,et al. Glucose Variability , 2016, Journal of diabetes science and technology.
[2] B. Davis,et al. Design of FLAT-SUGAR: Randomized Trial of Prandial Insulin Versus Prandial GLP-1 Receptor Agonist Together With Basal Insulin and Metformin for High-Risk Type 2 Diabetes , 2015, Diabetes Care.
[3] R. Vigersky. Escaping the Hemoglobin A1c-Centric World in Evaluating Diabetes Mellitus Interventions , 2015, Journal of diabetes science and technology.
[4] B. Zinman,et al. Association between 7 years of intensive treatment of type 1 diabetes and long-term mortality. , 2015, JAMA.
[5] S. Matthaei. Assessing the value of the Ambulatory Glucose Profile in clinical practice , 2014 .
[6] M. Evans,et al. Consensus recommendations for the use of Ambulatory Glucose Profile in clinical practice , 2014 .
[7] P. Jhund,et al. Changes in diabetes-related complications in the United States. , 2014, The New England journal of medicine.
[8] J. Upadhyay,et al. Changes in diabetes-related complications in the United States. , 2014, The New England journal of medicine.
[9] Harlan M Krumholz,et al. National trends in US hospital admissions for hyperglycemia and hypoglycemia among Medicare beneficiaries, 1999 to 2011. , 2014, JAMA internal medicine.
[10] P. Cryer. Glycemic Goals in Diabetes: Trade-off Between Glycemic Control and Iatrogenic Hypoglycemia , 2014, Diabetes.
[11] Desmond E. Williams,et al. Changes in diabetes-related complications in the United States, 1990-2010. , 2014, The New England journal of medicine.
[12] R. Ozaki,et al. Severe Hypoglycemia Identifies Vulnerable Patients With Type 2 Diabetes at Risk for Premature Death and All-Site Cancer: The Hong Kong Diabetes Registry , 2014, Diabetes Care.
[13] Desmond E. Williams,et al. Changes in diabetes-related complications in the United States. , 2014, The New England journal of medicine.
[14] A. Goto,et al. Severe hypoglycaemia and cardiovascular disease: systematic review and meta-analysis with bias analysis , 2013, BMJ.
[15] E. Simonsick,et al. Association between hypoglycemia and dementia in a biracial cohort of older adults with diabetes mellitus. , 2013, JAMA internal medicine.
[16] J. Saaddine,et al. Achievement of goals in U.S. diabetes care, 1999-2010. , 2013, The New England journal of medicine.
[17] D. Klonoff,et al. Recommendations for standardizing glucose reporting and analysis to optimize clinical decision making in diabetes: the Ambulatory Glucose Profile (AGP). , 2013, Diabetes technology & therapeutics.
[18] W. D. Willis,et al. Medical resource use, disturbance of daily life and burden of hypoglycemia in insulin-treated patients with diabetes: results from a European online survey , 2013, Expert review of pharmacoeconomics & outcomes research.
[19] Yongming Qu,et al. Rate of hypoglycemia in insulin-treated patients with type 2 diabetes can be predicted from glycemic variability data. , 2012, Diabetes technology & therapeutics.
[20] P. Cryer. Severe Hypoglycemia Predicts Mortality in Diabetes , 2012, Diabetes Care.
[21] L. Blonde,et al. Comparative effectiveness of basal-bolus versus premix analog insulin on glycemic variability and patient-centered outcomes during insulin intensification in type 1 and type 2 diabetes: a randomized, controlled, crossover trial. , 2012, The Journal of clinical endocrinology and metabolism.
[22] L. Monnier,et al. Glycemic Variability: Can We Bridge the Divide Between Controversies? , 2011, Diabetes Care.
[23] J. DeVries,et al. A Decrease in Glucose Variability Does Not Reduce Cardiovascular Event Rates in Type 2 Diabetic Patients After Acute Myocardial Infarction , 2011, Diabetes Care.
[24] R. Heine,et al. HbA1c and mean blood glucose show stronger associations with cardiovascular disease risk factors than do postprandial glycaemia or glucose variability in persons with diabetes: the A1C-Derived Average Glucose (ADAG) study , 2010, Diabetologia.
[25] I. Hirsch,et al. Beyond hemoglobin A1c--need for additional markers of risk for diabetic microvascular complications. , 2010, JAMA.
[26] Howard Zisser,et al. Improved quality of glycemic control and reduced glycemic variability with use of continuous glucose monitoring. , 2009, Diabetes technology & therapeutics.
[27] B. Zinman,et al. Modern-day clinical course of type 1 diabetes mellitus after 30 years' duration: the diabetes control and complications trial/epidemiology of diabetes interventions and complications and Pittsburgh epidemiology of diabetes complications experience (1983-2005). , 2009, Archives of internal medicine.
[28] David Rodbard,et al. Interpretation of continuous glucose monitoring data: glycemic variability and quality of glycemic control. , 2009, Diabetes technology & therapeutics.
[29] P. Wilson,et al. Effects of Prandial Versus Fasting Glycemia on Cardiovascular Outcomes in Type 2 Diabetes: The HEART2D trial , 2009, Diabetes Care.
[30] R. Holman,et al. 10-year follow-up of intensive glucose control in type 2 diabetes. , 2008, The New England journal of medicine.
[31] Robert Cuddihy,et al. Characterizing glucose exposure for individuals with normal glucose tolerance using continuous glucose monitoring and ambulatory glucose profile analysis. , 2008, Diabetes technology & therapeutics.
[32] B. Zinman,et al. Effect of Glycemic Exposure on the Risk of Microvascular Complications in the Diabetes Control and Complications Trial—Revisited , 2008, Diabetes.
[33] J. DeVries,et al. Glucose fluctuations and activation of oxidative stress in patients with type 1 diabetes , 2007, Diabetologia.
[34] M. Fisher,et al. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) , 2007 .
[35] Michael Brownlee,et al. The Effect of Glucose Variability on the Risk of Microvascular Complications in Type 1 Diabetes , 2007, Diabetes Care.
[36] B. Zinman,et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. , 2005, The New England journal of medicine.
[37] C. McDonnell,et al. A novel approach to continuous glucose analysis utilizing glycemic variation. , 2005, Diabetes technology & therapeutics.
[38] UK Prospective Diabetes Study Group. UK prospective diabetes study (UKPDS) , 2004, Diabetologia.
[39] P. Cryer,et al. Hypoglycaemia: The limiting factor in the glycaemic management of Type I and Type II Diabetes* , 2002, Diabetologia.
[40] R. Holman,et al. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. , 1998 .
[41] Uk-Prospective-Diabetes-Study-Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) , 1998, The Lancet.
[42] S. Genuth,et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. , 1993, The New England journal of medicine.
[43] S. Colagiuri,et al. The Diabetes Control and Complications Trial , 1983, Henry Ford Hospital medical journal.
[44] W. F. Taylor,et al. Mean Amplitude of Glycemic Excursions, a Measure of Diabetic Instability , 1970, Diabetes.